S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Tenax Therapeutics Stock Forecast, Price & News

-0.09 (-7.03%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
91,628 shs
Average Volume
785,211 shs
Market Capitalization
$30.00 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TENX News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Tenax Therapeutics logo

About Tenax Therapeutics

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.


TENX: Imatinib IND Cleared & PK Study Near End
November 18, 2021 |  finance.yahoo.com
TENX: FDA Approves Phase 3 LEVO-CTS Protocol Amendment
October 26, 2021 |  finance.yahoo.com
TENX: Second Quarter Results
September 20, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.37 per share


Net Income
$-9.85 million
Pretax Margin




Free Float
Market Cap
$30.00 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.48 out of 5 stars

Medical Sector

128th out of 1,392 stocks

Pharmaceutical Preparations Industry

52nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

Is Tenax Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Tenax Therapeutics stock.
View analyst ratings for Tenax Therapeutics
or view top-rated stocks.

How has Tenax Therapeutics' stock price been impacted by Coronavirus?

Tenax Therapeutics' stock was trading at $1.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TENX shares have increased by 14.4% and is now trading at $1.19.
View which stocks have been most impacted by COVID-19

When is Tenax Therapeutics' next earnings date?

Tenax Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Tenax Therapeutics

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) issued its quarterly earnings data on Tuesday, November, 16th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02.
View Tenax Therapeutics' earnings history

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Tenax Therapeutics's stock reverse split before market open on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for TENX?

1 analysts have issued twelve-month target prices for Tenax Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Tenax Therapeutics' share price to reach $5.00 in the next year. This suggests a possible upside of 320.2% from the stock's current price.
View analysts' price targets for Tenax Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the following people:
  • Mr. Anthony A. DiTonno, CEO & Director (Age 73, Pay $662.2k)
  • Mr. Michael B. Jebsen, Pres & CFO (Age 50, Pay $525.83k)
  • Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
  • Mr. Doug Randall, Exec. VP of Commercial & Bus. Operations
  • Dr. Douglas Hay, Sr. VP of Regulatory Affairs
  • Dr. Stuart Rich M.D., Chairman of Scientific Advisory Board, Chief Medical Officer & Director (Age 71)

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Gofen & Glossberg LLC IL (15.15%), Renaissance Technologies LLC (0.41%) and PNC Financial Services Group Inc. (0.28%). Company insiders that own Tenax Therapeutics stock include Armistice Capital Master Fund, Armistice Capital, Llc and Ronald R Blanck.
View institutional ownership trends for Tenax Therapeutics

Which major investors are selling Tenax Therapeutics stock?

TENX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Tenax Therapeutics
or view top insider-selling stocks.

Which major investors are buying Tenax Therapeutics stock?

TENX stock was purchased by a variety of institutional investors in the last quarter, including Gofen & Glossberg LLC IL, and PNC Financial Services Group Inc.. Company insiders that have bought Tenax Therapeutics stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, and Ronald R Blanck.
View insider buying and selling activity for Tenax Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Tenax Therapeutics?

Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $1.19.

How much money does Tenax Therapeutics make?

Tenax Therapeutics has a market capitalization of $30.00 million. The specialty pharmaceutical company earns $-9.85 million in net income (profit) each year or ($2.65) on an earnings per share basis.

How many employees does Tenax Therapeutics have?

Tenax Therapeutics employs 10 workers across the globe.

When was Tenax Therapeutics founded?

Tenax Therapeutics was founded in 1967.

What is Tenax Therapeutics' official website?

The official website for Tenax Therapeutics is www.tenaxthera.com.

Where are Tenax Therapeutics' headquarters?

Tenax Therapeutics is headquartered at ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.